This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Study Demonstrates AspenBio Pharma’s AppyScore Multi-Marker Blood Test Highly Predictive For Absence Of Acute Appendicitis In Children With Abdominal Pain

The final results from AspenBio Pharma’s (NASDAQ: APPY) 503-patient pilot study of AppyScore™ will be presented from the podium at the annual meeting of the Society for Academic Emergency Medicine being held in Chicago, May 9-12.

AppyScore is a multi-marker blood-based test panel consisting of the company’s patented MRP 8/14 biomarker and C-reactive protein, along with white blood cell count. AppyScore is designed to aid emergency physicians in the identification of patients at low risk when acute appendicitis is suspected due to abdominal pain. The AppyScore test is in development and not yet approved for use. Abdominal pain is the number one reason for hospital emergency department visits, and appendectomy is the number one reason for emergency abdominal surgery.

Enrollment and delivery of the total patient samples for the 2011 pilot study was completed in December 2011, and included pediatric and adolescent patients ages 2-20 with symptoms suspicious for acute appendicitis who were enrolled at 11 hospital sites across the country. Final data analysis using the multi-marker panel on the total 503 patient samples collected in the 2011 pilot study was recently finalized and demonstrated results for the AppyScore test at a negative predictive value of 97%, sensitivity of 96%, and specificity of 43%.

"Evaluating children for appendicitis is difficult, and strategies have been sought to improve the precision of the diagnosis,” said David S. Huckins, M.D., a clinical investigator in the AppyScore pilot study. “Computed tomography (CT) is widely used, but there are concerns regarding the large dose of ionizing radiation and risk of subsequent radiation-induced malignancy. I believe that the AppyScore results demonstrated in this study are very encouraging.”

In the U.S., approximately 10 million people annually enter hospital emergency rooms with abdominal pain. Currently, CT scanning is frequently used for screening of appendicitis due to the lack of other more definitive tools. However, CT scans take time, are expensive, and published studies have reported increased concern among clinicians about the potential harmful effects of CT radiation.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,798.49 -14.90 -0.08%
S&P 500 2,090.11 +1.24 0.06%
NASDAQ 5,127.5250 +11.3820 0.22%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs